Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Vaccines and Vaccination: Feature Papers
share announcement

Vaccines and Vaccination: Feature Papers

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 30 June 2024 | Viewed by 14114

Special Issue Editor

Dr. Pedro Plans-Rubió

E-Mail Website
Guest Editor
1. Public Health Agency of Catalonia, Department of Health of Catalonia, 08005 Barcelona, Spain
2. Ciber of Epidemiology and Public Health (CIBERESP), 28028 Madrid, Spain
Interests: vaccination programs; preventive interventions; epidemiology of vaccine-preventable diseases; seroepidemiology; cost-effectiveness analysis of vaccines and health programs; metabolic risk factors of chronic diseases; health policy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue seeks to collect high-quality review papers on vaccine research, vaccination, and public health. Vaccines are among the most cost-effective medicines, but vaccination programs must overcome multiple challenges to achieve their expected outcomes. In this Special Issue, we will collect comprehensive review articles (5000 words or more) that include the most recent research results and findings in relation to vaccination and public health; effectiveness, relative effectiveness, herd immunity and cost-effectiveness of vaccines; factors associated with the vaccination coverage at the national, regional, and local level; disease modelling; factors associated with vaccination hesitancy and vaccination confidence; the management of vaccination programs; advanced vaccination information systems; and the quality assessment of vaccination programs.  

Dr. Pedro Plans-Rubió
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine research
  • vaccination
  • public health
  • effectiveness
  • herd immunity
  • cost-effectiveness of vaccines
  • factors associated with the vaccination coverage
  • disease modelling
  • factors associated with vaccination hesitancy and vaccination confidence
  • management of vaccination programs
  • advanced vaccination information systems
  • quality assessment of vaccination programs

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

15 pages, 799 KiB  
Article
Acceptance of the COVID-19 Vaccine by Prisoners and Staff in Spanish Prisons
by Nancy Vicente-Alcalde, Sorina Madalina Sferle, Carlos Franco-Paredes and José Tuells
Vaccines 2023, 11(10), 1547; https://doi.org/10.3390/vaccines11101547 - 29 Sep 2023
Viewed by 824
Abstract
The COVID-19 vaccination of prisoners and prison staff represents a public health intervention to reduce the impact of the pandemic in conglomerate settings. In Spanish prisons, the road map of the Ministry of Health was followed to protect the population at risk. We [...] Read more.
The COVID-19 vaccination of prisoners and prison staff represents a public health intervention to reduce the impact of the pandemic in conglomerate settings. In Spanish prisons, the road map of the Ministry of Health was followed to protect the population at risk. We conducted a cross-sectional study to assess the acceptance of COVID-19 vaccination by prisoners and prison staff in a prison in Alicante, Spain. We analyzed data obtained through a standardized, self-administered, and anonymous questionnaire; 1016 prisoners and 288 prison staff responded to the survey. The majority of inmates and staff reported no history of symptomatic COVID-19, 90.15% and 91.66%, respectively. Respondents reported that 88.72% agreed to be vaccinated and 89.64% would recommend the vaccine to others. Approximately 89% believe that the benefit of getting vaccinated against COVID-19 is greater than the risk, and 70.55% reported that vaccination should be mandatory for inmates and staff to participate in some activities. The acceptance of COVID-19 vaccination among prisoners and prison staff is high in a Provincial Prison in Spain. Elevated acceptance of COVID-19 vaccination in prisons is a major factor in public health intervention and vaccine equity. Full article
(This article belongs to the Special Issue Vaccines and Vaccination: Feature Papers)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

20 pages, 2939 KiB  
Review
Oncolytic Viruses: An Inventory of Shedding Data from Clinical Trials and Elements for the Environmental Risk Assessment
by Sheela Onnockx, Aline Baldo and Katia Pauwels
Vaccines 2023, 11(9), 1448; https://doi.org/10.3390/vaccines11091448 - 01 Sep 2023
Cited by 1 | Viewed by 2159
Abstract
Attenuated and/or genetically modified oncolytic viruses (OV) gain increasing interest as a promising approach for cancer therapy. Beside the assessment of subject safety, quality and efficacy aspects of medicinal products for human use, genetically modified viruses are also governed by EU regulatory frameworks [...] Read more.
Attenuated and/or genetically modified oncolytic viruses (OV) gain increasing interest as a promising approach for cancer therapy. Beside the assessment of subject safety, quality and efficacy aspects of medicinal products for human use, genetically modified viruses are also governed by EU regulatory frameworks requiring an environmental risk assessment (ERA). An important element to be assessed as part of the ERA is the incidence of exposure to OV of individuals, other than the trial subjects, and the environment. The evidence-based evaluation of shedding data is considered to be decisive in that context, as it may impact the OV capacity to be transmitted. This is particularly true for OV still able to (conditionally) replicate as opposed to replication-defective viral vectors commonly used in gene therapy or vaccination. To our knowledge, this article presents the most extensive and up-to-date review of shedding data reported with OV employed in clinics. Besides the identification of a topical need for improving the collection of shedding data, this article aims at providing an aid to the design of an appropriate shedding study, thereby relying on and further complementing principles described in existing guidelines issued by European and international institutions. Full article
(This article belongs to the Special Issue Vaccines and Vaccination: Feature Papers)
►▼ Show Figures

Figure 1

34 pages, 527 KiB  
Review
Living with HIV and Getting Vaccinated: A Narrative Review
by Andrea De Vito, Agnese Colpani, Mattia Trunfio, Vito Fiore, Giulia Moi, Marco Fois, Nicola Leoni, Stefano Ruiu, Sergio Babudieri, Andrea Calcagno and Giordano Madeddu
Vaccines 2023, 11(5), 896; https://doi.org/10.3390/vaccines11050896 - 25 Apr 2023
Cited by 2 | Viewed by 1715
Abstract
After 40 years of its appearance, human immunodeficiency virus (HIV) infection remains a leading public health challenge worldwide. Since the introduction of antiretroviral treatment (ART), HIV infection has become a chronic condition, and people living with HIV could have life expectancies close to [...] Read more.
After 40 years of its appearance, human immunodeficiency virus (HIV) infection remains a leading public health challenge worldwide. Since the introduction of antiretroviral treatment (ART), HIV infection has become a chronic condition, and people living with HIV could have life expectancies close to those of the general population. People with HIV often have an increased risk of infection or experience more severe morbidity following exposure to vaccine-preventable diseases. Nowadays, several vaccines are available against bacteria and viruses. However, national and international vaccination guidelines for people with HIV are heterogeneous, and not every vaccine is included. For these reasons, we aimed to perform a narrative review about the vaccinations available for adults living with HIV, reporting the most updated studies performed for each vaccine among this population. We performed a comprehensive literature search through electronic databases (Pubmed—MEDLINE and Embase) and search engines (Google Scholar). We included English peer-reviewed publications (articles and reviews) on HIV and vaccination. Despite widespread use and guideline recommendations, few vaccine trials have been conducted in people with HIV. In addition, not all vaccines are recommended for people with HIV, especially for those with low CD4 cells count. Clinicians should carefully collect the history of vaccinations and patients’ acceptance and preferences and regularly check the presence of antibodies for vaccine-preventable pathogens. Full article
(This article belongs to the Special Issue Vaccines and Vaccination: Feature Papers)
26 pages, 4975 KiB  
Review
Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID
by Manish Dhawan, Ali A. Rabaan, Sara Alwarthan, Mashael Alhajri, Muhammad A. Halwani, Amer Alshengeti, Mustafa A. Najim, Ameen S. S. Alwashmi, Ahmad A. Alshehri, Saleh A. Alshamrani, Bashayer M. AlShehail, Mohammed Garout, Saleh Al-Abdulhadi, Shamsah H. Al-Ahmed, Nanamika Thakur and Geetika Verma
Vaccines 2023, 11(3), 699; https://doi.org/10.3390/vaccines11030699 - 19 Mar 2023
Cited by 14 | Viewed by 5795
Abstract
The COVID-19 pandemic has caused havoc all around the world. The causative agent of COVID-19 is the novel form of the coronavirus (CoV) named SARS-CoV-2, which results in immune system disruption, increased inflammation, and acute respiratory distress syndrome (ARDS). T cells have been [...] Read more.
The COVID-19 pandemic has caused havoc all around the world. The causative agent of COVID-19 is the novel form of the coronavirus (CoV) named SARS-CoV-2, which results in immune system disruption, increased inflammation, and acute respiratory distress syndrome (ARDS). T cells have been important components of the immune system, which decide the fate of the COVID-19 disease. Recent studies have reported an important subset of T cells known as regulatory T cells (Tregs), which possess immunosuppressive and immunoregulatory properties and play a crucial role in the prognosis of COVID-19 disease. Recent studies have shown that COVID-19 patients have considerably fewer Tregs than the general population. Such a decrement may have an impact on COVID-19 patients in a number of ways, including diminishing the effect of inflammatory inhibition, creating an inequality in the Treg/Th17 percentage, and raising the chance of respiratory failure. Having fewer Tregs may enhance the likelihood of long COVID development in addition to contributing to the disease’s poor prognosis. Additionally, tissue-resident Tregs provide tissue repair in addition to immunosuppressive and immunoregulatory activities, which may aid in the recovery of COVID-19 patients. The severity of the illness is also linked to abnormalities in the Tregs’ phenotype, such as reduced expression of FoxP3 and other immunosuppressive cytokines, including IL-10 and TGF-beta. Hence, in this review, we summarize the immunosuppressive mechanisms and their possible roles in the prognosis of COVID-19 disease. Furthermore, the perturbations in Tregs have been associated with disease severity. The roles of Tregs are also explained in the long COVID. This review also discusses the potential therapeutic roles of Tregs in the management of patients with COVID-19. Full article
(This article belongs to the Special Issue Vaccines and Vaccination: Feature Papers)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

21 pages, 1656 KiB  
Systematic Review
How Well the Constructs of Health Belief Model Predict Vaccination Intention: A Systematic Review on COVID-19 Primary Series and Booster Vaccines
by Yam B. Limbu and Rajesh K. Gautam
Vaccines 2023, 11(4), 816; https://doi.org/10.3390/vaccines11040816 - 07 Apr 2023
Cited by 6 | Viewed by 2600
Abstract
This systematic review synthesizes the findings of quantitative studies examining the relationships between Health Belief Model (HBM) constructs and COVID-19 vaccination intention. We searched PubMed, Medline, CINAHL, Web of Science, and Scopus using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [...] Read more.
This systematic review synthesizes the findings of quantitative studies examining the relationships between Health Belief Model (HBM) constructs and COVID-19 vaccination intention. We searched PubMed, Medline, CINAHL, Web of Science, and Scopus using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and identified 109 eligible studies. The overall vaccination intention rate was 68.19%. Perceived benefits, perceived barriers, and cues to action were the three most frequently demonstrated predictors of vaccination intention for both primary series and booster vaccines. For booster doses, the influence of susceptibility slightly increased, but the impact of severity, self-efficacy, and cues to action on vaccination intention declined. The impact of susceptibility increased, but severity’s effect declined sharply from 2020 to 2022. The influence of barriers slightly declined from 2020 to 2021, but it skyrocketed in 2022. Conversely, the role of self-efficacy dipped in 2022. Susceptibility, severity, and barriers were dominant predictors in Saudi Arabia, but self-efficacy and cues to action had weaker effects in the USA. Susceptibility and severity had a lower impact on students, especially in North America, and barriers had a lower impact on health care workers. However, cues to action and self-efficacy had a dominant influence among parents. The most prevalent modifying variables were age, gender, education, income, and occupation. The results show that HBM is useful in predicting vaccine intention. Full article
(This article belongs to the Special Issue Vaccines and Vaccination: Feature Papers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop